MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuvanted with fibroblast stimulating lipopeptide 1 (FSL-1). Immunological results indicate that the glycosylated tricomponent vaccine candidate has elicited both humoral and cellular immune responses. The induced antibodies could effectively bind to MCF-7. Furthermore, the vaccine exhibited an obvious reduction in tumour burden.

中文翻译：

---

基于MUC1的三组分疫苗与FSL-1结合用于癌症免疫治疗的设计。

由于MUC1在许多肿瘤细胞上的过度表达和异常糖基化模式，它是癌症疫苗的诱人靶标。但是，MUC1的低免疫原性和免疫耐受性限制了其应用。在这里，我们设计了基于MUC1的三组分抗肿瘤疫苗，佐以成纤维细胞刺激脂肽1（FSL-1）。免疫学结果表明，糖基化三组分疫苗候选物已引起体液和细胞免疫反应。诱导的抗体可以有效结合MCF-7。此外，该疫苗显示出肿瘤负担的明显减少。